针对组蛋白去乙酰化酶治疗亨廷顿病。
Targeting histone deacetylases for the treatment of Huntington's disease.
机构信息
Translational Cancer Research Group, Department of Clinical Medicine, Institute of Molecular Medicine, Trinity Centre for Health Sciences, St James's Hospital, James's Street, Dublin, Ireland.
出版信息
CNS Neurosci Ther. 2010 Dec;16(6):348-61. doi: 10.1111/j.1755-5949.2010.00184.x.
Abstract
Huntington's disease is a debilitating neurodegenerative condition with significant burdens on both patient and healthcare costs. Despite the identification of the causative element, an expanded toxic polyglutamine tract in the mutant Huntingtin protein, treatment options for patients with this disease remain limited. In the following review I assess the current evidence suggesting that a family of important regulatory proteins known as histone deacetylases may be an important therapeutic target in the treatment of this disease.
摘要
亨廷顿病是一种使人虚弱的神经退行性疾病，给患者和医疗保健成本都带来了巨大负担。尽管已经确定了致病因素，即突变亨廷顿蛋白中扩展的毒性多聚谷氨酰胺链，但这种疾病的治疗选择仍然有限。在下面的综述中，我评估了目前的证据，表明一组称为组蛋白去乙酰化酶的重要调节蛋白可能是治疗这种疾病的重要治疗靶点。
相似文献
1
Targeting histone deacetylases for the treatment of Huntington's disease.
CNS Neurosci Ther. 2010 Dec;16(6):348-61. doi: 10.1111/j.1755-5949.2010.00184.x.
2
Histone deacetylase inhibitors: a novel therapeutic approach to Huntington's disease (complex mechanism of neuronal death).
Curr Alzheimer Res. 2006 Sep;3(4):403-8. doi: 10.2174/156720506778249407.
3
[Histone deacetylase inhibitors as therapeutic agents for polyglutamine disorders].
Zhonghua Yi Xue Yi Chuan Xue Za Zhi. 2010 Feb;27(1):52-5. doi: 10.3760/cma.j.issn.1003-9406.2010.01.011.
4
Epigenetic Mechanisms Involved in Huntington's Disease Pathogenesis.
J Huntingtons Dis. 2015;4(1):1-15. doi: 10.3233/JHD-159001.
5
Epigenetics of Huntington's Disease.
Adv Exp Med Biol. 2017;978:277-299. doi: 10.1007/978-3-319-53889-1_15.
6
Differential contributions of Caenorhabditis elegans histone deacetylases to huntingtin polyglutamine toxicity.
J Neurosci. 2006 Mar 8;26(10):2830-8. doi: 10.1523/JNEUROSCI.3344-05.2006.
7
Epigenetic treatment of neurological disease.
Epigenomics. 2011 Aug;3(4):431-50. doi: 10.2217/epi.11.67.
8
Histone deacetylase inhibitors arrest polyglutamine-dependent neurodegeneration in Drosophila.
Nature. 2001 Oct 18;413(6857):739-43. doi: 10.1038/35099568.
9
Epigenetic modifications as novel therapeutic targets for Huntington's disease.
Epigenomics. 2014 Jun;6(3):287-97. doi: 10.2217/epi.14.19.
10
Transcriptional dysregulation in Huntington's disease: The role of histone deacetylases.
Pharmacol Res. 2015 Oct;100:157-69. doi: 10.1016/j.phrs.2015.08.002. Epub 2015 Aug 6.
引用本文的文献
1
Neuroinflammation and the role of epigenetic-based therapies for Huntington's disease management: the new paradigm.
Inflammopharmacology. 2024 Jun;32(3):1791-1804. doi: 10.1007/s10787-024-01477-0. Epub 2024 Apr 23.
2
14-3-3 proteins-a moonlight protein complex with therapeutic potential in neurological disorder: in-depth review with Alzheimer's disease.
Front Mol Biosci. 2024 Feb 5;11:1286536. doi: 10.3389/fmolb.2024.1286536. eCollection 2024.
3
Epigenetics and Metabolism in Health and Disease.
Front Genet. 2018 Sep 18;9:361. doi: 10.3389/fgene.2018.00361. eCollection 2018.
4
Computer Aided Drug Design and its Application to the Development of Potential Drugs for Neurodegenerative Disorders.
Curr Neuropharmacol. 2018;16(6):740-748. doi: 10.2174/1570159X15666171016163510.
5
LBH589, A Hydroxamic Acid-Derived HDAC Inhibitor, is Neuroprotective in Mouse Models of Huntington's Disease.
J Huntingtons Dis. 2016 Dec 15;5(4):347-355. doi: 10.3233/JHD-160226.
6
The potential of epigenetic therapies in neurodegenerative diseases.
Front Genet. 2014 Jul 14;5:220. doi: 10.3389/fgene.2014.00220. eCollection 2014.
7
Small non-coding RNAs add complexity to the RNA pathogenic mechanisms in trinucleotide repeat expansion diseases.
Front Mol Neurosci. 2013 Dec 3;6:45. doi: 10.3389/fnmol.2013.00045.
8
Huntington's disease: the past, present, and future search for disease modifiers.
Yale J Biol Med. 2013 Jun 13;86(2):217-33. Print 2013 Jun.
9
Stress-induced epigenetic transcriptional memory of acetylcholinesterase by HDAC4.
Proc Natl Acad Sci U S A. 2012 Dec 26;109(52):E3687-95. doi: 10.1073/pnas.1209990110. Epub 2012 Dec 10.
10
A double-edged sword with therapeutic potential: an updated role of autophagy in ischemic cerebral injury.
CNS Neurosci Ther. 2012 Nov;18(11):879-86. doi: 10.1111/cns.12005. Epub 2012 Sep 24.
本文引用的文献
1
Huntingtin interacts with the cue domain of gp78 and inhibits gp78 binding to ubiquitin and p97/VCP.
PLoS One. 2010 Jan 26;5(1):e8905. doi: 10.1371/journal.pone.0008905.
2
Identification of phenylbutyrate-generated metabolites in Huntington disease patients using parallel liquid chromatography/electrochemical array/mass spectrometry and off-line tandem mass spectrometry.
Anal Biochem. 2010 Apr 15;399(2):152-61. doi: 10.1016/j.ab.2010.01.010. Epub 2010 Jan 13.
3
IKK phosphorylates Huntingtin and targets it for degradation by the proteasome and lysosome.
J Cell Biol. 2009 Dec 28;187(7):1083-99. doi: 10.1083/jcb.200909067. Epub 2009 Dec 21.
4
Transcriptional dysregulation of coding and non-coding genes in cellular models of Huntington's disease.
Biochem Soc Trans. 2009 Dec;37(Pt 6):1270-5. doi: 10.1042/BST0371270.
5
Phosphorylation of threonine 3: implications for Huntingtin aggregation and neurotoxicity.
J Biol Chem. 2009 Oct 23;284(43):29427-36. doi: 10.1074/jbc.M109.013193. Epub 2009 Aug 26.
6
Valproate ameliorates the survival and the motor performance in a transgenic mouse model of Huntington's disease.
Pharmacol Biochem Behav. 2009 Nov;94(1):148-53. doi: 10.1016/j.pbb.2009.08.001. Epub 2009 Aug 19.
7
Accumulation of ubiquitin conjugates in a polyglutamine disease model occurs without global ubiquitin/proteasome system impairment.
Proc Natl Acad Sci U S A. 2009 Aug 18;106(33):13986-91. doi: 10.1073/pnas.0906463106. Epub 2009 Jul 30.
8
Phosphoproteomic analysis of human embryonic stem cells.
Cell Stem Cell. 2009 Aug 7;5(2):204-13. doi: 10.1016/j.stem.2009.06.002.
9
Oxidative stress induced lung cancer and COPD: opportunities for epigenetic therapy.
J Cell Mol Med. 2009 Sep;13(9A):2800-21. doi: 10.1111/j.1582-4934.2009.00845.x. Epub 2009 Jul 7.
10
Rhes, a striatal specific protein, mediates mutant-huntingtin cytotoxicity.
Science. 2009 Jun 5;324(5932):1327-30. doi: 10.1126/science.1172871.
Zotero 插件